Enzymatica AB (publ) (STO:ENZY)

Sweden · Delayed Price · Currency is SEK

2.590

+0.390 (17.73%)

Nov 4, 2026, 5:29 PM CET

Enzymatica AB Earnings Call Transcripts

Fiscal Year 2025

Study Result
Recent independent studies confirm ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, as shown in both athlete-based and cell culture models. The product demonstrated strong efficacy and safety, with results expected to apply to the general population.

Read full transcript →

Press release